Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872125 · ClinicalTrials.gov registry record · Phase 3
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
A Phase 3 study of Dravet Syndrome, sponsored by Stoke Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT06872125 is a Phase 3 study of Dravet Syndrome that is actively recruiting participants, run by Stoke Therapeutics. The registered enrollment target is 170 participants, above the 96-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (77% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06872125, a Phase 3 study of Dravet Syndrome, is actively recruiting participants, sponsored by Stoke Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Conditions Studied
Interventions
- DRUG zorevunersen
- OTHER Sham Comparator
Study Locations (20)
California
- Cedars Sinai Medical Center - Los Angeles
- Children's Hospital of Orange County - Orange
- USCF Medical Center - San Francisco
Florida
- Nemours Children's Health - Jacksonville
- Nicklaus Children's Hospital - Miami
- Advent Health Neuroscience Research Institute - Orlando
New York
- NYU Langone Health - New York
- Weill Cornell Medicine - New York
- University of Rochester Medical Center - Rochester
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06872125
The ClinicalTrials.gov registry entry for NCT06872125 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (77% higher). The listed sponsor is Stoke Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 2 interventions - of which zorevunersen is the first listed.
NCT06872125 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06872125 about?
NCT06872125 is a clinical study titled "A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome". The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
What is the current status of trial NCT06872125?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2025-06-04. Estimated completion is 2028-10.
What conditions does trial NCT06872125 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT06872125?
The interventions under investigation include: zorevunersen (DRUG), Sham Comparator (OTHER).
Who is sponsoring clinical trial NCT06872125?
This trial is sponsored by Stoke Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872125 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
-
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
GABA Biomarkers in Dravet Syndrome
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.